News

Success stories - view case studies of companies that have successfully raised funds through OION.

View details of OION's Next Investment Meeting

Back to news item list.

1stJuly 2010
ATLANTIC HEALTHCARE

Dr Huw Jones appointed CEO, Atlantic Pharmaceuticals to lead growth of Atlantic Healthcare’s therapeutics division
Cambridge UK, Sydney Australia, 2nd July 2010: Atlantic Healthcare Limited, an international specialist-led healthcare company, announces that Dr Huw Jones has been appointed Chief Executive of Atlantic Healthcare’s therapeutics division, Atlantic Pharmaceuticals Limited and joins the board of Atlantic Healthcare.

Huw becomes Chief Executive Officer, Atlantic Pharmaceuticals, with responsibility for Atlantic Healthcare’s pharmaceutical activities and, in particular, the development and international commercialisation of alicaforsen. Alicaforsen is an anti-inflammatory, intercellular adhesion molecule (“ICAM-1”) inhibitor that acts by switching off a key protein that causes inflammation in the gastro-intestinal tract. Alicaforsen is now available through a Named Patient Supply programme for patients suffering from pouchitis and is being developed for other inflammatory bowel disease (IBD) conditions.

Huw holds a PhD in pharmacology from the University of Birmingham, UK and has over twenty years experience in the pharmaceutical sector. He has supervised over fifteen product launches in Europe and has completed numerous product and company acquisitions and divestments.

Most recently Huw was a director of Ardana plc and was previously President, Europe for CV Therapeutics Inc, a NASDAQ-quoted pharmaceutical company recently acquired by Gilead Sciences Inc. for US$1.4bn. Other appointments include Senior Vice President, Northern Europe, for Elan Pharmaceuticals where he helped build the European operations from a start-up into a 600 person division and UK marketing director for SmithKlineBeecham Pharmaceuticals, now part of GlaxoSmithKline plc.